Document Detail


Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.
MedLine Citation:
PMID:  20441717     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Treatment with olanzapine is associated with obesity, diabetes mellitus, and dyslipidemia. Reports have indicated that orally disintegrating tablets (ODT) cause less weight gain than oral standard tablets (OST). The aim of this study was to compare the effect of short-term treatment with these 2 distinct olanzapine formulations on glucose and lipid metabolism in healthy men. METHOD: Twelve healthy men (mean ± SEM age: 25.1 ± 5.5 years) received olanzapine ODT (10 mg od, 8 days), olanzapine OST (10 mg od, 8 days), or no intervention in a randomized crossover design. At breakfast and dinner, glucose, insulin, free fatty acids (FFA), and triglyceride concentrations were measured at 10-minute intervals from 30 minutes prior to 2 hours after ingestion of standard meals. Leptin and adiponectin concentrations were measured at 20- and 30-minute intervals, respectively, between 0000h-1200h. Physical activity was assessed with an accelerometer. Fuel oxidation was measured in fasting condition by indirect calorimetry. The study was conducted from April 2006 through September 2006. RESULTS: Treatment with olanzapine ODT and OST equally elevated the homeostasis model assessment of insulin resistance (HOMA-IR) (P = .005). At breakfast, both formulations equally increased fasting and postprandial triglyceride concentrations (P = .013 and P = .005, respectively) while decreasing fasting and postprandial FFA concentrations (P = .004 and P = .009, respectively). Body weight, body composition, physical activity, or fuel oxidation did not differ between treatment modalities. CONCLUSIONS: Eight days of treatment with both olanzapine formulations similarly increased HOMA-IR and triglyceride concentrations and decreased FFA concentrations in response to standard meals without affecting anthropometrics or physical activity. These data suggest that olanzapine hampers insulin action via mechanistic routes other than body adiposity or physical inactivity. TRIAL REGISTRATION: controlled-trials.com. Identifier: ISRCTN17632637.
Authors:
Solrun Vidarsdottir; Pauline Vlug; Ferdinand Roelfsema; Marijke Frölich; Hanno Pijl
Related Documents :
3897287 - Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. e...
9916137 - Effects of free fatty acids on glucose transport and irs-1-associated phosphatidylinosi...
10364187 - Novel form of lipolysis induced by leptin.
16804037 - Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponecti...
22393537 - Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.
9409247 - Relation of ldl size to the insulin resistance syndrome and coronary heart disease in a...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-04-20
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  71     ISSN:  1555-2101     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-06     Completed Date:  2010-10-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1205-11     Citation Subset:  IM    
Copyright Information:
© Copyright 2010 Physicians Postgraduate Press, Inc.
Affiliation:
Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The Netherlands.
Data Bank Information
Bank Name/Acc. No.:
ISRCTN/ISRCTN17632637
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiponectin / blood
Adult
Antipsychotic Agents / pharmacology*
Benzodiazepines / pharmacology*
Blood Glucose / metabolism
Cross-Over Studies
Dosage Forms
Energy Metabolism / drug effects
Fatty Acids, Nonesterified / blood
Homeostasis / drug effects*
Humans
Insulin / blood
Insulin Resistance / physiology*
Leptin / blood
Male
Motor Activity / physiology
Reference Values
Triglycerides / blood*
Young Adult
Chemical
Reg. No./Substance:
0/Adiponectin; 0/Antipsychotic Agents; 0/Blood Glucose; 0/Dosage Forms; 0/Fatty Acids, Nonesterified; 0/Leptin; 0/Triglycerides; 11061-68-0/Insulin; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Picture of the month: Phthirus
Next Document:  Association study of trauma load and SLC6A4 promoter polymorphism in posttraumatic stress disorder: ...